Nichole Tucker

Articles

Brentuximab Vedotin Shows Encouraging Responses Rates, Tolerability in Older Patients With Hodgkin Lymphoma

December 8th 2020

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

Ponatinib Elicits High Responses, Robust Outcomes in CP-CML Following TKI Failure

December 8th 2020

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

CD47-Directed TTI-622 Elicits Early Efficacy Signals in Relapsed/Refractory Lymphoma

December 6th 2020

December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.

Early Allogeneic HSCT With HLA-Matched Donor Improves Outcomes in Older Patients With Higher-Risk MDS

December 6th 2020

December 6, 2020 - Having a human leukocyte antigen–matching donor for allogeneic hematopoietic stem cell transplant has proven to lead to improved outcomes for patients who are between 50 and 75 years of age and have higher-risk myelodysplastic syndrome.

Oral Azacitidine Improves Health-Related QoL in AML

December 6th 2020

Oral azacitidine demonstrated sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

September 20th 2020

Potent and durable clinical activity was shown with pralsetinib as treatment of patients with RET-mutant advanced medullary thyroid cancer, regardless of the line of therapy.

QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial

September 20th 2020

Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.

Neoadjuvant Durvalumab Induces Responses in Resectable NSCLC, But High Postsurgical Mortality Ends Study

September 19th 2020

Neoadjuvant durvalumab achieved a satisfactory complete surgical resection rate in patients with resectable non–small cell lung cancer, demonstrating preliminary promise for this treatment strategy.

Study Explores Genomics of Race in Prostate Cancer

August 6th 2020

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC

June 23rd 2020

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

Pembrolizumab Added to Etoposide Plus Platinum Chemotherapy Provides Modest Survival Benefit in ES-SCLC

May 29th 2020

Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo.

Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors

May 29th 2020

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Scoring System Stratifies Risk of Heart Failure in Patients With Acute Leukemia

May 18th 2020

Baseline clinical characteristics coupled with measurable cardiac parameters can be used to predict the risk of heart failure among adults with acute leukemia who receive anthracycline-based therapy, according to recent study findings.

Scoring System Stratifies Risk of Heart Failure in Patients With Acute Leukemia

May 18th 2020

Cell-Free DNA Detects Adjuvant MRD Positivity and Disease Relapse in NSCLC

April 29th 2020

Circulating tumor DNA may be a biomarker for the detection of postsurgical minimal residual disease and for determining the clonality of relapsing disease.

cfDNA Assay Shows Predictive Value in Detecting Cancer, Tissue of Origin

April 29th 2020

A cell-free DNA test demonstrated the potential to detect cancer and predict tissue of origin in patients with a suspicion of cancer, according to findings from the Circulating Cell-free Genome Atlas study presented at the 2020 AACR Virtual Annual Meeting I.

Expert Highlights Contributing Elements to Hemopoietic Recovery From CAR T-Cell Therapy

March 26th 2020

Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.

Researchers Building on Darolutamide Success in Prostate Cancer

February 26th 2020

Martin T. King, MD, PhD, discusses the INTREPId trial exploring darolutamide plus radiation therapy in patients with prostate cancer.